Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma... Show more
LUCD may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In of 28 cases where LUCD's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for LUCD just turned positive on May 01, 2025. Looking at past instances where LUCD's MACD turned positive, the stock continued to rise in of 30 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where LUCD advanced for three days, in of 187 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 104 cases where LUCD Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 37 cases where LUCD's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .
The Momentum Indicator moved below the 0 level on May 06, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on LUCD as a result. In of 67 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
LUCD moved below its 50-day moving average on April 10, 2025 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for LUCD crossed bearishly below the 50-day moving average on April 16, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where LUCD declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. LUCD’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (35.088) is normal, around the industry mean (24.028). P/E Ratio (0.000) is within average values for comparable stocks, (79.397). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (5.667). Dividend Yield (0.000) settles around the average of (0.018) among similar stocks. P/S Ratio (15.314) is also within normal values, averaging (42.137).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LUCD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 89, placing this stock worse than average.
Industry MedicalSpecialties
A.I.dvisor indicates that over the last year, LUCD has been loosely correlated with NOTV. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if LUCD jumps, then NOTV could also see price increases.
Ticker / NAME | Correlation To LUCD | 1D Price Change % | ||
---|---|---|---|---|
LUCD | 100% | -1.60% | ||
NOTV - LUCD | 34% Loosely correlated | -13.73% | ||
CRL - LUCD | 30% Poorly correlated | -3.37% | ||
INGN - LUCD | 26% Poorly correlated | +1.43% | ||
BMRA - LUCD | 26% Poorly correlated | -6.52% | ||
ESTA - LUCD | 24% Poorly correlated | -1.49% | ||
More |